Skip to content

The Effectiveness and the Safety of Acupuncture for Symptomatic Care of Hemodialysis Patients: A Case-series

Acupuncture for Symptomatic Care of Hemodialysis Patients: a Case-series

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00883831
Enrollment
20
Registered
2009-04-20
Start date
2009-04-30
Completion date
2010-01-31
Last updated
2010-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease, Hemodialysis

Keywords

Acupuncture, Hemodialysis, Symptom, end stage renal disease, chronic kidney disease, supportive care

Brief summary

Purpose: Hemodialysis-dependent patients with an end-stage renal disease (ESRD) suffer from a number of distressing symptoms, such as pain, poor mental health, fatigue, sleep disturbance and pruritus. These negatively influence health-related quality of life in ESRD patients, and some of them result in increased mortality and hospitalization. Acupuncture is a widely employed treatment on several chronic disease or condition. Adjunctive use of acupuncture with conventional treatment could be a possible therapeutic option to establish an optimal care for ESRD patients who experiences co-morbid conditions or complications of hemodialysis. Due to its non-pharmacologic feature, the effects of acupuncture without involving altered pharmacokinetics and drug-interactions in hemodialysis patients, might be another strong point compared to other pharmacological interventions. However, little information is available for the effects and the safety of acupuncture for symptomatic care of hemodialysis patients. Thus, the investigators propose whether acupuncture could be a effective and safe therapeutic modality for a number of patient-reported symptoms in hemodialysis-dependent patients with ESRD.

Detailed description

This trial is a case-series, with a nested-qualitative study at the end of follow-up. Acupuncture treatment will be provided biweekly for 6 weeks, namely total 12 sessions, and follow-up period will be 4 weeks after the end of treatment. Changes of symptoms, quality of life and occured adverse events will be assessed during study procedure. Patients who agreed joining qualitative research will be interviewed about their experiences of acupuncture in detail.

Interventions

PROCEDUREIndividualized manual acupuncture

Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.

Sponsors

Korea Institute of Oriental Medicine
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* over 19 years old * started hemodialysis at least 3 months ago * receiving hemodialysis 3 times a week regularly * equilibrated Kt/V ≥ 1.2 * willingness to participate in this study

Exclusion criteria

* acute/chronic liver disease * events of life-threatening cardiovascular disease within 6 months * events of life-threatening neurological disorder within 6 months * current/past history of neoplasm * hemorrhagic disorders * drug abuse/alcoholism * other infectious disease including active tuberculosis * history of the use of acupuncture, moxibustion or herbs within 1 month

Design outcomes

Primary

MeasureTime frame
Measure Your Medical Outcome Profile2 (MYMOP)Evaluated at baseline, post-treatment, and 4 weeks after post-treatment (total 3 times)

Secondary

MeasureTime frame
Kidney Disease Quality of Life-SF V1.3 (KDQOL-SF V 1.3) questionnaireEvaluated at baseline, post-treatment, and 4 weeks after post-treatment (total 3 times)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026